N/A N=35

Hyperglycemia and Mitochondrial Function in The Endothelium of Humans

Diabetes · Hyperglycemia

Bottom Line

View on ClinicalTrials.gov: NCT02682342 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Jan 2025

Primary outcome: Primary: Change in Mitochondrial Network Complexity of Endothelial Cells as Measured by Mitochondrial Network Fragment Ratio

Study Design & Population

Study type: Observational
Phase: N/A
Interventions: 75 g glucose solution (Other)
Age: Adult, Older Adult · 21+ yrs
Sex: All
Sponsor: Medical College of Wisconsin
Primary completion: Feb 2022

Outcome Measures

Outcome	Result	p-value
PRIMARY Change in Mitochondrial Network Complexity of Endothelial Cells as Measured by Mitochondrial Network Fragment Ratio	—	—

Summary

In this study, the investigators will test the hypothesis that acute in vivo exposure to hyperglycemia increases mitochondrial network fragmentation and mitochondrial reactive oxygen species production (ROS) production in human arterial endothelial cells.

Eligibility Criteria

Inclusion Criteria

Adult age 21 to 70
No evidence of metabolic syndrome or diabetes, hypertension (BP≥140/90), or high cholesterol (LDL≥160) at the time of screening.

Exclusion Criteria

History of stroke, peripheral arterial disease, or coronary artery disease (as defined by the presence of at least one coronary stenosis ≥ 40% on angiography or by confirmed history of myocardial infarction by standard criteria).
History of bleeding disorders.
Evidence of other evident major illness including chronic renal insufficiency (plasma creatinine > 1.4 for women or 1.5 for men), liver disease (liver enzymes greater than 2.5 x normal), and cancer
currently undergoing therapy or had therapy for cancer within 1 year of enrollment.
Pregnancy as determined by urinary human chorionic gonadotropin beta test
Thienopyridine, anti-thrombin/Xa, or warfarin therapy at time of screening
On medication for cholesterol or blood pressure

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02682342). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.